Interleukin (IL)-33 is a tissue-derived nuclear cytokine belonging to the IL-1 family. Stimulation-2 (ST2) is the only known IL-33 receptor. ST2 signals mostly on immune cells found within tissues, such as regulatory T cells (Treg cells), CD8+ T cells, and natural killer (NK) cells. Therefore, the IL-33/ST2 signaling pathway is important in the immune system. IL-33 deficiency impairs Treg cell function. ST2 signaling is also increased in active Treg cells, providing a new approach for Treg-related immunotherapy. The IL-33/ST2 signaling pathway regulates multiple immune-related cells by activating various intracellular kinases and factors in the tumor microenvironment (TME). Here, we review the latest studies on the role of the IL-33/ST2 signaling pathway in TME and Treg immunotherapy.
SakaguchiSSakaguchiNAsanoMItohMTodaM. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol1995;155:1151–64
2.
KhattriRCoxTYasaykoSARamsdellF. An essential role for Scurfin in CD4+CD25+ T regulatory cells.Nat Immunol2003;4:337–42
3.
SinghKHjortMThorvaldsonLSandlerS. Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice.Sci Rep2015;5:7767
4.
MayneCGWilliamsCB. Induced and natural regulatory T cells in the development of inflammatory bowel disease.Inflamm Bowel Dis2013;19:1772–88
5.
HatzioannouABanosASakelaropoulosTFedonidisCVidaliMSKohneMHandlerKBoonLHenriquesAKoliarakiVGeorgiadisPZoidakisJTermentziABeyerMChavakisTBoumpasDTsirigosAVerginisP. An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion.Nat Immunol2020;21:75–85
6.
AimoAMiglioriniPVergaroGFranziniMPassinoCMaiselAEmdinM. The IL-33/ST2 pathway, inflammation and atherosclerosis: trigger and target?Int J Cardiol2018;267:188–92
7.
SakuishiKApetohLSullivanJMBlazarBRKuchrooVKAndersonAC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med2010;207:2187–94
8.
CayrolCGirardJP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family.Immunol Rev2018;281:154–68
9.
MattaBMLottJMMathewsLRLiuQRosboroughBRBlazarBRTurnquistHR. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells.J Immunol2014;193:4010–20
10.
PeineMMarekRMLohningM. IL-33 in T cell differentiation, function, and immune homeostasis.Trends Immunol2016;37:321–33
11.
MolofskyABSavageAKLocksleyRM. Interleukin-33 in tissue homeostasis, injury, and inflammation.Immunity2015;42:1005–19
12.
AlvarezFFritzJHPiccirilloCA. Pleiotropic effects of IL-33 on CD4(+) T cell differentiation and effector functions.Front Immunol2019;10:522
13.
PastilleEWasmerMHAdamczykAVuVPMagerLFPhuongNNTPalmieriVSimillionCHansenWKasperSSchulerMMuggliBMcCoyKDBuerJZlobecIWestendorfAMKrebsP. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.Mucosal Immunol2019;12:990–1003
14.
YanagisawaKTakagiTTsukamotoTTetsukaTTominagaS. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1.FEBS Lett1993;318:83–7
15.
GarlandaCDinarelloCAMantovaniA. The interleukin-1 family: back to the future.Immunity2013;39:1003–18
16.
ZhaoWHuZ. The enigmatic processing and secretion of interleukin-33.Cell Mol Immunol2010;7:260–2
ShenJXLiuJZhangGJ. Interleukin-33 in malignancies: friends or foes?Front Immunol2018;9:3051
19.
ZhangXChenWZengPXuJDiaoH. The contradictory role of interleukin-33 in immune cells and tumor immunity.Cancer Manag Res2020;12:7527–37
20.
BrunnerSMSchiechlGFalkWSchlittHJGeisslerEKFichtner-FeiglS. Interleukin-33 prolongs allograft survival during chronic cardiac rejection.Transpl Int2011;24:1027–39
21.
GriesenauerBJiangHYangJZhangJRamadanAMEgbosiubaJCampaKPaczesnyS. ST2/MyD88 deficiency protects mice against acute graft-versus-host disease and spares regulatory T cells.J Immunol2019;202:3053–64
22.
SiedeJFrohlichADatsiAHegazyANVargaDVHolecskaVSaitoHNakaeSLohningM. IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFbeta release.PLoS ONE2016;11:e0161507
23.
Overacre-DelgoffeAEChikinaMDadeyREYanoHBrunazziEAShayanGHorneWMoskovitzJMKollsJKSanderCShuaiYNormolleDPKirkwoodJMFerrisRLDelgoffeGMBrunoTCWorkmanCJVignaliDAA. Interferon-gamma drives Treg fragility to promote anti-tumor immunity.Cell2017;169:1130.e11–41
24.
SmithgallMDComeauMRYoonBRKaufmanDArmitageRSmithDE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells.Int Immunol2008;20:1019–30
25.
SmithDE. The biological paths of IL-1 family members IL-18 and IL-33.J Leukoc Biol2011;89:383–92
26.
SchieringCKrausgruberTChomkaAFrohlichAAdelmannKWohlfertEAPottJGriseriTBollrathJHegazyANHarrisonOJOwensBMJLohningMBelkaidYFallonPGPowrieF. The alarmin IL-33 promotes regulatory T-cell function in the intestine.Nature2014;513:564–8
27.
WhitesideTL. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.Expert Opin Ther Targets2018;22:353–63
28.
TokerAOhashiPS. Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: implications for combination immunotherapy approaches.Adv Cancer Res2019;144:193–261
29.
BlackburnSDShinHHainingWNZouTWorkmanCJPolleyABettsMRFreemanGJVignaliDAWherryEJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.Nat Immunol2009;10:29–37
30.
TanakaASakaguchiS. Targeting Treg cells in cancer immunotherapy.Eur J Immunol2019;49:1140–6
31.
TanakaASakaguchiS. Regulatory T cells in cancer immunotherapy.Cell Res2017;27:109–18
32.
DyckLMillsKHG. Immune checkpoints and their inhibition in cancer and infectious diseases.Eur J Immunol2017;47:765–79
33.
RibattiDVaccaA. The role of microenvironment in tumor angiogenesis.Genes Nutr2008;3:29–34
34.
ChalubinskiMWojdanKLuczakEGorzelakPBorowiecMGajewskiARudnickaKChmielaMBroncelM. IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms.Vascul Pharmacol2015;73:57–63
35.
ChoiYSChoiHJMinJKPyunBJMaengYSParkHKimJKimYMKwonYG. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production.Blood2009;114:3117–26
36.
ZhangYDavisCShahSHughesDRyanJCAltomareDPenaMM. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.Mol Carcinog2017;56:272–87
37.
GaoKLiXZhangLBaiLDongWGaoKShiGXiaXWuLZhangL. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice.Cancer Lett2013;335:463–71
38.
ChangCPHuMHHsiaoYPWangYC. ST2 Signaling in the tumor microenvironment.Adv Exp Med Biol2020;1240:83–93
39.
QiLZhangQMiaoYKangWTianZXuDXiaoWFangF. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.Int J Cancer2020;146:1421–34
40.
BonillaWVFrohlichASennKKallertSFernandezMJohnsonSKreutzfeldtMHegazyANSchrickCFallonPGKlemenzRNakaeSAdlerHMerklerDLohningMPinschewerDD. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses.Science2012;335:984–9
41.
BourgeoisEVanLPSamsonMDiemSBarraARogaSGombertJMSchneiderEDyMGourdyPGirardJPHerbelinA. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production.Eur J Immunol2009;39:1046–55
GaoXWangXYangQZhaoXWenWLiGLuJQinWQiYXieFJiangJWuCZhangXChenXTurnquistHZhuYLuB. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.J Immunol2015;194:438–45
44.
NoelGArshadMIFilliolAGenetVRauchMLucas-ClercCLehuenAGirardJPPiquet-PellorceCSamsonM. Ablation of interaction between IL-33 and ST2+ regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration.Am J Physiol Gastrointest Liver Physiol2016;311:G313–123
45.
VillarrealDOWiseMCWaltersJNReuschelELChoiMJObeng-AdjeiNYanJMorrowMPWeinerDB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.Cancer Res2014;74:1789–800
46.
WhitesideTL. Induced regulatory T cells in inhibitory microenvironments created by cancer.Expert Opin Biol Ther2014;14:1411–25
47.
TakeuchiYNishikawaH. Roles of regulatory T cells in cancer immunity.Int Immunol2016;28:401–9
48.
ChaoJLSavagePA. Unlocking the complexities of tumor-associated regulatory T cells.J Immunol2018;200:415–21
49.
LiuCChikinaMDeshpandeRMenkAVWangTTabibTBrunazziEAVignaliKMSunMStolzDBLafyatisRAChenWDelgoffeGMWorkmanCJWendellSGVignaliDAA. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+) T cell-derived interferon-gamma.Immunity2019;51:381e6–97
50.
Overacre-DelgoffeAEVignaliDAA. Treg fragility: a prerequisite for effective antitumor immunity.Cancer Immunol Res2018;6:882–7
51.
MooreKWde Waal MalefytRCoffmanRLO’GarraA. Interleukin-10 and the interleukin-10 receptor.Annu Rev Immunol2001;19:683–765
52.
MuraiMTurovskayaOKimGMadanRKarpCLCheroutreHKronenbergM. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis.Nat Immunol2009;10:1178–84
53.
SawantDVYanoHChikinaMZhangQLiaoMLiuCCallahanDJSunZSunTTabibTPennathurACorryDBLuketichJDLafyatisRChenWPoholekACBrunoTCWorkmanCJVignaliDAA. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion.Nat Immunol2019;20:724–35
54.
DiefenhardtPNoskoAKlugerMARichterJVWegscheidCKobayashiYTiegsGHuberSFlavellRAStahlRAKSteinmetzOM. IL-10 receptor signaling empowers regulatory T cells to control Th17 responses and protect from GN.J Am Soc Nephrol2018;29:1825–37
55.
HsuPSantner-NananBHuMSkarrattKLeeCHStormonMWongMFullerSJNananR. IL-10 Potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1.J Immunol2015;195:3665–74
56.
WingKOnishiYPrieto-MartinPYamaguchiTMiyaraMFehervariZNomuraTSakaguchiS. CTLA-4 control over Foxp3+ regulatory T cell function.Science2008;322:271–5
57.
TakahashiTTagamiTYamazakiSUedeTShimizuJSakaguchiNMakTWSakaguchiS. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.J Exp Med2000;192:303–10
58.
WalunasTLLenschowDJBakkerCYLinsleyPSFreemanGJGreenJMThompsonCBBluestoneJA. CTLA-4 can function as a negative regulator of T cell activation.Immunity1994;1:405–13
59.
KormanAJPeggsKSAllisonJP. Checkpoint blockade in cancer immunotherapy.Adv Immunol2006;90:297–339
60.
DuXTangFLiuMSuJZhangYWuWDevenportMLazarskiCAZhangPWangXYePWangCHwangEZhuTXuTZhengPLiuY. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.Cell Res2018;28:416–32
61.
ChenLFliesDB. Molecular mechanisms of T cell co-stimulation and co-inhibition.Nat Rev Immunol2013;13:227–42
62.
KumarPBhattacharyaPPrabhakarBS. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.J Autoimmun2018;95:77–99
63.
SansevieroEO’BrienEMKarrasJRShabanehTBAksoyBAXuWZhengCYinXXuXKarakousisGCAmaravadiRKNamBTurkMJHammerbacherJRubinsteinMPSchuchterLMMitchellTCLiuQStoneEL. Anti-CTLA-4 activates intratumoral NK cells and combined with IL15/IL15Ralpha complexes enhances tumor control.Cancer Immunol Res2019;7:1371–80
64.
SpainLDiemSLarkinJ. Management of toxicities of immune checkpoint inhibitors.Cancer Treat Rev2016;44:51–60
65.
WeberJSPostowMLaoCDSchadendorfD. Management of adverse events following treatment with anti-programmed death-1 agents.Oncologist2016;21:1230–40
66.
PittJMVetizouMDaillereRRobertiMPYamazakiTRoutyBLepagePBonecaIGChamaillardMKroemerGZitvogelL. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors.Immunity2016;44:1255–69
67.
SalehRElkordE. Treg-mediated acquired resistance to immune checkpoint inhibitors.Cancer Lett2019;457:168–79
68.
KnochelmannHMDwyerCJBaileySRAmayaSMElstonDMMazza-McCrannJMPaulosCM. When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Cell Mol Immunol2018;15:458–69
69.
ZhuJYamaneHPaulWE. Differentiation of effector CD4 T cell populations (*).Annu Rev Immunol2010;28:445–89
70.
ChenJYangJQiaoYLiX. Understanding the regulatory roles of natural killer T cells in rheumatoid arthritis: T helper cell differentiation dependent or independent?Scand J Immunol2016;84:197–203
71.
MailerRKJolyALLiuSEliasSTegnerJAnderssonJ. IL-1beta promotes Th17 differentiation by inducing alternative splicing of FOXP3.Sci Rep2015;5:14674
72.
NoackMMiossecP. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases.Autoimmun Rev2014;13:668–77
73.
AfzaliBLombardiGLechlerRILordGM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.Clin Exp Immunol2007;148:32–46
74.
LiHWangLPangYJiangZLiuZXiaoHChenHGeXLanHXiaoY. In patients with chronic aplastic anemia, bone marrow-derived MSCs regulate the Treg/Th17 balance by influencing the Notch/RBP-J/FOXP3/RORgammat pathway.Sci Rep2017;7:42488
75.
YuliasihYRahmawatiLDPutriRM. Th17/Treg ratio and disease activity in systemic lupus erythematosus.Caspian J Intern Med2019;10:65–72
76.
SonJChoJWParkHJMoonJParkSLeeHLeeJKimGParkSMLiraSAMckenzieANKimHYChoiCYLimYTParkSYKimHRParkSHShinECLeeIHaSJ. Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33/ST2 signaling.Cancer Immunol Res2020;8:1393–406
77.
TakenagaKAkimotoMKoshikawaNNagaseH. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.PLoS ONE2020;15:e0232230
78.
JovanovicIRadosavljevicGMitrovicMJuranicVLMcKenzieANArsenijevicNJonjicSLukicML. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma.Eur J Immunol2011;41:1902–12
79.
JovanovicIPPejnovicNNRadosavljevicGDPanticJMMilovanovicMZArsenijevicNNLukicML. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.Int J Cancer2014;134:1669–82
80.
ChoiMRSosmanJAZhangB. The Janus face of IL-33 signaling in tumor development and immune escape.Cancers2021;13:3281
81.
YueYLianJWangTLuoCYuanYQinGZhangBZhangY. Interleukin-33-nuclear factor-kappaB-CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells.Cancer Sci2020;111:795–806
82.
ZhuoCXuYYingMLiQHuangLLiDCaiSLiB. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.Immunol Res2015;61:338–47
83.
HuaWYuanAZhengWLiCCuiJPangZZhangLLiZGollRCuiG. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.Pathol Res Pract2016;212:106–12
84.
CuiGYuanALiZGollRFlorholmenJ. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis.Sci Rep2020;10:5892
85.
EissmannMFDijkstraCWoutersMABaloyanDMouradovDNguyenPMDavalos-SalasMPutoczkiTLSieberOMMariadasonJMErnstMMassonF. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-gamma-dependent manner.Cancer Immunol Res2018;6:409–21
86.
LiJHuangLZhaoHYanYLuJ. The role of interleukins in colorectal cancer.Int J Biol Sci2020;16:2323–39
87.
MagerLFRietherCSchurchCMBanzYWasmerMHStuberRTheocharidesAPLiXXiaYSaitoHNakaeSBaerlocherGMManzMGMcCoyKDMacphersonAJOchsenbeinAFBeutlerBKrebsP. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.J Clin Invest2015;125:2579–91
88.
LiuPSeidelNBodineDSpeckNTarleSCollinsFS. Acute myeloid leukemia with Inv (16) produces a chimeric transcription factor with a myosin heavy chain tail.Cold Spring Harb Symp Quant Biol1994;59:547–53
89.
LiuPPHajraAWijmengaCCollinsFS. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.Blood1995;85:2289–302
90.
WangYRichterLBeckerMAmadorCHydeRK. IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival.Sci Rep2019;9:1729
91.
CurranECorralesLKlineJ. Targeting the innate immune system as immunotherapy for acute myeloid leukemia.Front Oncol2015;5:83
92.
QinLDominguezDChenSFanJLongAZhangMFangDZhangYKuzelTMZhangB. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.Oncotarget2016;7:61069–80
93.
FranciscoLMSalinasVHBrownKEVanguriVKFreemanGJKuchrooVKSharpeAH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.J Exp Med2009;206:3015–29
94.
CaiJWangDZhangGGuoX. The role of PD-1/PD-L1 axis in Treg development and function: implications for cancer immunotherapy.Onco Targets Ther2019;12:8437–45
95.
AllegraAInnaoVTartariscoGPioggiaGCasciaroMMusolinoCGangemiS. The ST2/interleukin-33 axis in hematologic malignancies: the IL-33 paradox.Int J Mol Sci2019;20:5226
96.
LeushackeMTanSHWongASwathiYHajamohideenATanLTGohJWongEDenilSLIJMurakamiKBarkerN. Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach.Nat Cell Biol2017;19:774–86
97.
MeyerARGoldenringJR. Injury, repair, inflammation and metaplasia in the stomach.J Physiol2018;596:3861–7
98.
BaiFBaFYouYFengYTaoWWuCJiuMNieY. Decreased ST2 expression is associated with gastric cancer progression and pathogenesis.Oncol Lett2019;17:5761–7
99.
EissmannMFDijkstraCJarnickiAPhesseTBrunnbergJPohAREtemadiNTsantikosEThiemSHuntingtonNDHibbsMLBoussioutasAGrimbaldestonMABuchertMO’DonoghueRJJMassonFErnstM. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization.Nat Commun2019;10:2735
100.
MaKLiXLvJLiuZZhangLCongHWangHShenFYueL. Correlations between CD4(+) FoxP3(+) Treg and expression of FoxM1 and Ki-67 in gastric cancer patients.Asia Pac J Clin Oncol2021;17:e63–9
101.
LiFSunYHuangJXuWLiuJYuanZ. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.Cancer Med2019;8:7330–44
102.
Kudo-SaitoCMiyamotoTImazekiHShojiHAokiKBokuN. IL33 is a key driver of treatment resistance of cancer.Cancer Res2020;80:1981–90
103.
LiAHerbstRHCannerDSchenkelJMSmithOCKimJYHillmanMBhutkarACuocoMSRappazzoCGRogersPDangCJerby-ArnonLRozenblatt-RosenOCongLBirnbaumMRegevAJacksT. IL-33 signaling alters regulatory T cell diversity in support of tumor development.Cell Rep2019;29:2998e8–3008
104.
AndreoneSGambardellaARManciniJLoffredoSMarcellaSLa SorsaVVarricchiGSchiavoniGMatteiF. Anti-tumorigenic activities of IL-33: a mechanistic insight.Front Immunol2020;11:571593
105.
BrownCYSadlonTHopeCMWongYYWongSLiuNWithersHBrownKBandaraVGundsambuuBPedersonSBreenJRobertsonSAForrestABeyerMBarrySC. Molecular insights into regulatory T-cell adaptation to self, environment, and host tissues: plasticity or loss of function in autoimmune disease.Front Immunol2020;11:1269
106.
SuzukiALelandPJoshiBHPuriRK. Targeting of IL-4 and IL-13 receptors for cancer therapy.Cytokine2015;75:79–88
107.
ZaissDMvan LoosdregtJGorlaniABekkerCPGroneASibiliaMvan BergenenHenegouwenPMRooversRCCofferPJSijtsAJ. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.Immunity2013;38:275–84
108.
LinLLiYLiuMLiQLiuQLiR. The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.Aging2020;12:1685–703
109.
LimHXChoiSChoDKimTS. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.Immunol Cell Biol2017;95:99–107
110.
AfferniCBuccioneCAndreoneSGaldieroMRVarricchiGMaroneGMatteiFSchiavoniG. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity.Front Immunol2018;9:2601
